Stroke / illamående

Deuterium-enriched pyridinonecarboxamides and derivatives

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

SUMMARY OF THE INVENTION The present invention is concerned with deuterium-enriched pyridinone carboxamides and derivatives thereof of formula I, ##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),

Deuterium-enriched pyridinonecarboxamides and derivatives

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

SUMMARY OF THE INVENTION The present invention is concerned with deuterium-enriched pyridinonecarboxamides and derivatives thereof of formula 1, ##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

Thienopyridinone compounds and methods of treatment

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The invention generally relates to the field of serotonin (5-hydroxytryptamine, or 5-HT) receptor modulators, e.g., agonists, partial agonists, inverse agonists, antagonists, and more particularly to new thienopyridinone compounds, the synthesis and use of these compounds and

Thienopyridinone compounds and methods of treatment

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The invention generally relates to the field of serotonin (5-hydroxytryptamine, or 5-HT) receptor modulators, e.g., agonists, partial agonists, inverse agonists, antagonists, and more particularly to new thienopyridinone compounds, the synthesis and use of these compounds and

Synthesis of thienopyridinone compounds and related intermediates

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The invention generally relates to the field of serotonin (5-hydroxytryptamine, or 5-HT) receptor modulators, e.g., agonists, partial agonists, inverse agonists, antagonists, and more particularly to new thienopyridinone compounds, the synthesis and use of these compounds and

Urea compounds and their use as enzyme inhibitors

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty

Urea compounds and their use as enzyme inhibitors

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty

Compressed tablet containing .DELTA.9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. National Phase of International Patent Application No. PCT/NL2014/050746, filed Oct. 29, 2014, published on May 7, 2015 as WO 2015/065180 A1, which claims priority to European Patent Application No. 13190577.0, filed Oct. 29, 2013.

N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

This application is a 371 of PCT/GB93/02130, Oct. 14, 1993. This invention relates to novel compounds having pharmacological activity, to a process for their preparation and to their use as pharmaceuticals. European Journal of Pharmacology 146 (1988 ), 187-188, and Naunyn-Schmiedeberg's Arch.

stroke/illamående

Deuterium-enriched pyridinonecarboxamides and derivatives

Deuterium-enriched pyridinonecarboxamides and derivatives

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Thienopyridinone compounds and methods of treatment

Thienopyridinone compounds and methods of treatment

Synthesis of thienopyridinone compounds and related intermediates

Urea compounds and their use as enzyme inhibitors

Urea compounds and their use as enzyme inhibitors

Compressed tablet containing .DELTA.9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment

N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen